Foot and Mouth Disease Vaccine Market Report 2026

The foot and mouth disease vaccine market size has grown strongly in recent years. It will grow from $2.83 billion in 2025 to $3.11 billion in 2026 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to frequent outbreaks of foot-and-mouth disease, increasing livestock population, government-led vaccination programs, advancements in conventional vaccine technologies, rising awareness of animal health management.

The foot and mouth disease vaccine market size is expected to see rapid growth in the next few years. It will grow to $4.57 billion in 2030 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to development of rapid response and diva vaccines, expansion of multi-species vaccination coverage, adoption of oil-adjuvanted and aluminum hydroxide-based vaccines, increasing government funding for FMD control, rising investments in cold chain and distribution infrastructure. Major trends in the forecast period include increasing adoption of emergency vaccines for rapid outbreak response, rising focus on multi-species fmd vaccination programs, development of diva (differentiating infected from vaccinated animals) vaccines, expansion of government-led immunization campaigns, growing use of oil-adjuvanted and aluminum hydroxide-based vaccines.

The expanding livestock population is driving the growth of the foot and mouth disease vaccine market. Livestock refers to farm animals raised, housed, and utilized by humans, including cows, horses, and pigs. The rise in livestock numbers is driven by increased demand for animal products. As livestock populations grow, the risk of foot and mouth disease prevalence rises, which can boost market growth. For example, in July 2023, according to the FAO, a US-based United Nations agency, global milk production in 2023 was projected to reach 944 million tonnes, up 0.9% from 2022, reflecting increasing demand for animal-source foods as incomes rise and diets shift toward protein. Therefore, the growing livestock population is expected to propel the foot and mouth disease vaccine market.

The rise in healthcare expenditure is also anticipated to drive the growth of the foot and mouth disease vaccine market. Healthcare expenditure refers to the total spending on healthcare goods and services within a specific period. Increased healthcare investment supports research and development in veterinary medicine, enabling the creation of more effective and advanced vaccines, including those for preventing foot and mouth disease in animals. For instance, in November 2025, according to the Organisation for Economic Co-operation and Development (OECD), a France-based intergovernmental economic organization, healthcare systems in member countries allocated an average of 9.3% of GDP to health in 2024, with real per capita spending showing renewed growth after stagnation in 2023, and average spending per person exceeding 3% annual growth. Consequently, rising healthcare expenditure is driving the expansion of the foot and mouth disease vaccine market.

Leading players in the foot and mouth disease vaccine market are developing innovative initiatives, such as clinical trials, to enhance their market presence and profitability. Clinical trials are research studies that test new treatments and medications. For example, in June 2023, the Department of Animal Husbandry and Dairying, an India-based ministry, launched the third phase of FMD vaccination under NADCP. This phase represents a comprehensive effort to control FMD in cattle and forms part of a broader plan to manage FMD through vaccination by 2025, with the goal of eradication by 2030. The initiative also aims to improve local production and expand exports of milk and other animal products.

Major companies operating in the foot and mouth disease vaccine market are Godrej Agrovet Limited, Biogénesis Bagó S.A., Indian Immunologicals Limited, Merck & Co. Inc., Intervet India Private Limited, China Animal Husbandry Group, C.H. Boehringer Sohn AG & Co. KG, FGBI‑ARRIAH, NAVETCO NATIONAL VETERINARY JOINT STOCK COMPANY, Ceva Santé Animale, Alivira Animal Health Limited, Zoetis Inc., Dong Bang Co. Ltd., The Spirit Jinyu Biological Pharmaceutical Co. Ltd., Biovet Private Limited, MEVAC, SPIC Gene Science Technology Development Co. Ltd., VETAL Animal Health Products Inc., Southern Cross Group, VECOL S.A, Limor de Colombia.

Asia-Pacific was the largest region in the foot and mouth disease vaccine market in 2025. The regions covered in the foot and mouth disease vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the foot and mouth disease vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the foot-and-mouth disease vaccine market by raising import costs of vaccine ingredients, adjuvants, and delivery systems, particularly affecting regions such as Asia-Pacific and Africa where FMD prevalence is high. Livestock and multi-species vaccination programs are most affected. Positive impacts include encouraging local production of vaccines and promoting domestic research and development for more cost-effective and readily available vaccine solutions.

The foot and mouth disease vaccine market research report is one of a series of new reports that provides foot and mouth disease vaccine market statistics, including foot and mouth disease vaccine industry global market size, regional shares, competitors with a foot and mouth disease vaccine market share, detailed foot and mouth disease vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the foot and mouth disease vaccine industry. This foot and mouth disease vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Foot-and-mouth disease (FMD) vaccines serve as a crucial intervention to enhance the immune defenses of animals against the highly contagious foot-and-mouth disease. This disease poses a severe threat to all cloven-hoofed animals, including cattle, sheep, goats, camelids, deer, and pigs. Clinical signs of FMD in animals include elevated body temperature and the development of blisters, primarily affecting the feet and mouth.

The main categories of foot-and-mouth disease vaccines include conventional vaccines, oil-based vaccines, aluminum hydroxide/saponin-based vaccines, and emergency vaccines tailored for cattle, pigs, sheep, goats, and other susceptible animals. Conventional vaccines typically consist of inactivated disease-causing organisms or pathogen-derived proteins (antigens). These antigens mimic the infectious agent, working to stimulate the immune system. The goal is to prime the immune system, enabling it to respond more rapidly and effectively if the animal is exposed to the actual infectious agent. Distribution channels for foot-and-mouth disease vaccines are diverse and include government organizations, distributors/pharmacies, private veterinary services, and other relevant distribution channels. This widespread availability ensures that these vaccines can be efficiently disseminated to protect susceptible animal populations and prevent the spread of foot-and-mouth disease.

The foot and mouth disease vaccine market consist of sales of inactivated vaccine, viral vector vaccine, adenovirus, virus-like particle vaccines, baculovirus, plant-produced empty capsids, RNA vaccine, and DNA vaccine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.